Bart Barlogie, MD, PhD | Authors

HILL COUNTRY OBGYN ASSOCIATES PA

7900 FM 1826 STE 200

Articles

Arkansas Pioneers 'Total Therapy' for Multiple Myeloma

January 01, 1996

LITTLE ROCK, Ark--Little prog-ress has been made during the last 30 years toward improving the prognosis of patients with myeloma. Because of the patients' often brittle condition and advanced age, dose intensity concepts had not been evaluated until the late Tim McElwain from the Royal Marsden Hospital reported responses to high-dose melphalan [Alkeran] at 140 mg/m² in patients with refractory disease or high-risk newly diagnosed patients.